We posit that MCL-1 inhibition via miR-32 or sabutoclax can be effective therapy, alone or in combination with other agents, in a variety of human melanoma subtypes that currently have no effective treatment options available in the clinic. The gene discussed is MCL1; the disease is melanoma.